Please Find Enclosed Herewith Outcome of the Board Meeting For Your Records for the Quarter Ended 30th June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board approved standalone unaudited financial results for Q1 FY26 (quarter ended 30 June 2025). Revenue from operations stood at Rs. 18.05 lakhs with total income of Rs. 18.05 lakhs. Total expenses were Rs. 12.69 lakhs, yielding a profit before tax of Rs. 5.36 lakhs and profit after tax of Rs. 4.01 lakhs (EPS Rs. 0.06), a swing from the Rs. 49.05 lakh loss reported in the previous quarter (Q4 FY25). For full-year FY25, the company reported a loss of Rs. 54.73 lakhs and its other equity sits in the negative at Rs. -109.77 lakhs. The board also appointed Mr. Shashank Kumar as Secretarial Auditor and Mr. Nishant Sharma as Internal Auditor for FY24-25, and approved a proposed name change from 'Boston Bio Systems Limited' to 'Boston Commerce Limited', subject to member and MCA approvals.
The return to a small quarterly profit is encouraging after a loss-making FY25, but the negative reserves position (other equity of Rs. -109.77 lakhs) remains a concern for long-term financial health. The proposed name change and new auditor appointments are administrative and unlikely to move the stock on their own.